Cell and Gene Therapy

AbelZeta Pharma Announces Agreement with AstraZeneca to Co-Develop a novel Glypican 3 (GPC3) Armored CAR-T Therapy in China

Published December. 15. 2023
cgt -AbelZeta Pharma Announces

AbelZeta, a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative cell therapies for cancer, inflammatory and immunological diseases, announced an agreement with AstraZeneca to co-develop C-CAR031, an autologous, armored GPC3-targeting chimeric antigen receptor T Cells (CAR-T) therapy, in hepatocellular carcinoma (HCC).C-CAR031 is based on a new GPC3-targeting CART (AZD5851), which is produced in China by AbelZeta and was created by AstraZeneca using their dominant negative armoring discovery platform, transforming growth factor-beta receptor II (TGFβRII).

HCC accounts for over 50% of all new cases worldwide, with 466 thousand new cases reported year, making it one of the most common malignancies and a leading cause of cancer-related deaths in China1. The greater China region accounts for about 45% of HCC-related mortality globally.2.

As per the terms of the deal, AstraZeneca will pay AbelZeta up front for co-developing and commercialising C-CAR031 in China. AstraZeneca is the only company developing, producing, and marketing AZD5851 outside of China; AbelZeta is also entitled to milestone payments and royalties for this work.

Preliminary safety, effectiveness, pharmacokinetics, and pharmacodynamic data from an investigator-initiated trial (IIT) in China demonstrating strong PK/PD profiles and promising anti-tumor activity for C-CAR031 in patients with advanced HCC were presented by the company at AACR 2023.

Source: AbelZeta

Get the free newsletter

Subscribe to IMAPAC for top news, trends & analysis

Cell and Gene Therapy World Summit Brochure

    Contact Form


    [honeypot email-address move-inline-css:true]

    IMAPAC requires your contact information to reach out to you about our products and services. You can unsubscribe from these communications at any time. For details on how to unsubscribe and to learn more about our privacy practices and our commitment to protecting your privacy, please review our Privacy Policy.

    Download Brochure Sample

      Contact Form


      [honeypot email-address move-inline-css:true]

      IMAPAC requires your contact information to reach out to you about our products and services. You can unsubscribe from these communications at any time. For details on how to unsubscribe and to learn more about our privacy practices and our commitment to protecting your privacy, please review our Privacy Policy.